<DOC>
	<DOCNO>NCT00089401</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop tumor cell divide stop grow die . Giving chemotherapy drug different way may kill tumor cell . PURPOSE : This phase II trial study well isolate hepatic perfusion melphalan work treat patient unresectable colorectal cancer metastasize liver .</brief_summary>
	<brief_title>Isolated Hepatic Perfusion With Melphalan Treating Patients With Unresectable Colorectal Cancer That Has Metastasized Liver</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response duration response patient unresectable colorectal cancer metastatic liver refractory first-line systemic chemotherapy treat isolated hepatic perfusion melphalan . Secondary - Determine pattern recurrence ( liver vs systemic ) patient treat regimen . - Determine hepatic progression-free overall survival patient treat regimen . - Determine time hepatic systemic progression patient treat regimen . - Determine quality life ( QOL ) patient treat regimen . - Correlate baseline QOL length survival patient treat regimen . OUTLINE : Patients undergo limited laparotomy determine extrahepatic disease visualize preoperative scanning present . Patients find peritoneal seed unresectable extrahepatic metastatic disease previously visualize scan receive isolate hepatic perfusion ( IHP ) . Remaining patient undergo IHP melphalan hyperthermia therapy . Liver perfusion continue 1 hour . Quality life assess baseline , 6 week , every 3-4 month 3 year . Patients follow 6 week , every 3-4 month 3 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal cancer Metastatic disease limit parenchyma liver Patients limited site extrahepatic disease AND dominant lifelimiting disease liver consider eligible provide extrahepatic site treat local ablative measure ( e.g. , resection external beam radiotherapy ) No evidence unresectable extrahepatic disease radiological study Unresectable hepatic disease define &gt; 3 site disease liver , bilobar disease , tumor abut major vascular ductal structure make anatomic resection liver function preservation impossible Measurable disease Refractory prior firstline systemic chemotherapy Disease progression completion treatment irinotecan oxaliplatincontaining regimen establish hepatic metastasis Treatment failure define disease progression evidence tumor growth OR new lesion image modality OR increase carcinoembryonic antigen ( CEA ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Hematocrit &gt; 27.0 % Platelet count &gt; 100,000/mm^3 WBC &gt; 3,000/mm^3 Hepatic Bilirubin &lt; 2.0 mg/dL PT ≤ 2 second upper limit normal ALT AST elevation secondary metastatic disease allow Chronic active hepatitis B C allow provide evidence cirrhosis pathology , radiologic study , physical exam No history venoocclusive disease No biopsy proven cirrhosis No evidence significant portal hypertension manifest ascites , esophageal varix endoscopy , radiologic study show significant collateral vessel around organ drain portal venous system No liver condition would preclude study therapy Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance &gt; 60 mL/min Cardiovascular LVEF ≥ 40 % No ischemic cardiac disease No history congestive heart failure Pulmonary Chronic obstructive pulmonary disease chronic pulmonary disease allow provided pulmonary function test ≥ 50 % predict Other Not pregnant nursing Negative pregnancy test No active infection Weight &gt; 30 kg PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior biologic therapy malignancy recover Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy malignancy recover Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy malignancy recover Surgery See Disease Characteristics Other No concurrent immunosuppressive drug No concurrent chronic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>